The DOI matches its Crossref record; 253 of the 253 references it cites were found in a registry or an index.
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Abstract
Nonalcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD) are the leading causes of chronic liver disease worldwide. NAFLD and ALD share pathophysiological, histological and genetic features and both alcohol and metabolic dysfunction coexist as aetiological factors in many patients with hepatic steatosis. A diagnosis of NAFLD requires the exclusion of significant alcohol consumption and other causes of liver disease. However, data suggest that significant alcohol consumption is often under-reported in patients classified as having NAFLD and that alcohol and metabolic factors interact to exacerbate the progression of liver disease. In this Review, we analyse existing data on the interaction between alcohol consumption and metabolic syndrome as well as the overlapping features and differences in the pathogenesis of ALD and NAFLD. We also discuss the clinical implications of the coexistence of alcohol consumption, of any degree, in patients with evidence of metabolic derangement as well as the use of alcohol biomarkers to detect alcohol intake. Finally, we summarize the evolving nomenclature of fatty liver disease and describe a recent proposal to classify patients at the intersection of NAFLD and ALD. We propose that, regardless of the presumed aetiology, patients with fatty liver disease should be evaluated for both metabolic syndrome and alcohol consumption to enable better prognostication and a personalized medicine approach.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our findings suggest that factors beyond alcohol consumption contribute to the rising prevalence of ALD and primary liver cancer [25,26].”
From Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021 (2025) · cites this paper as [25]
Citations
Cites
Items 201–253 of 253
Alcohol drinking patterns and the risk of fatty liver in Japanese men
Hiramine, Y., Imamura, Y., Uto, H., Koriyama, C., Horiuchi, M., Oketani, M., Hosoyamada, K., Kusano, K., Ido, A., & Tsubouchi, H. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0336-z · Cited by 53
Pennisi, G., Celsa, C., Giammanco, A., Spatola, F., & Petta, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225613 · Cited by 52
Sookoian, S. C., Flichman, D. M., Castaño, G. O., & Pirola, C. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13828 · Cited by 52
Whitfield, J. B., Masson, S., Liangpunsakul, S., Mueller, S., Aithal, G. P., Eyer, F., Gleeson, D. C., Thompson, A., Stickel, F., Soyka, M., et al. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000833 · Cited by 51
Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets
Bianco, C., Casirati, E., Malvestiti, F., & Valenti, L. V. C. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100284 · Cited by 51
The contribution of sterile inflammation to the fatty liver disease and the potential therapies
Shaker, M. E. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112789 · Cited by 51
Inflammasome activation in the liver: Focus on alcoholic and non-alcoholic steatohepatitis
Szabó, G., & Iracheta‐Vellve, A. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.06.012 · Cited by 46
NAFLD: Challenges and opportunities to address the public health problem in Latin America
Arab, J. P., Díaz, L. A., Dirchwolf, M., Mark, H. E., Lazarus, J. V., Vaughan, E. C., Méndez‐Sánchez, N., de Oliveira, C. P. M. S., Gadano, A. C., & Arrese, M. A. (2021) · Annals of Hepatology · doi:10.1016/j.aohep.2021.100359 · Cited by 46
Self-citationAn Update in Epigenetics in Metabolic-Associated Fatty Liver Disease
Rodríguez-Sanabria, J. S., Escutia-Gutiérrez, R., Rosas-Campos, R., Armendáriz‐Borunda, J., & Sandoval-Rodriguez, A. S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.770504 · Cited by 45
Singal, A. K., Kwo, P. Y., Kwong, A. J., Liangpunsakul, S., Louvet, A., Mandrekar, P., McClain, C. J., Mellinger, J. L., Szabó, G., Terrault, N. A., et al. (2021) · Hepatology · doi:10.1002/hep.32143 · Cited by 44
Self-citationEpigenetics of alcohol-related liver diseases
Habash, N. W., Sehrawat, T. S., Shah, V. H., & Cao, S. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100466 · Cited by 44
Hwang, S., Ren, T., & Gao, B. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0100 · Cited by 43
Epigenetics factors in nonalcoholic fatty liver disease
Pirola, C. J., & Sookoian, S. C. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1765772 · Cited by 43
Extracellular Vesicles in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease
Wu, D., Zhu, H., & Wang, H. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.707429 · Cited by 42
Decraecker, M., Dutartre, D., Hiriart, J., Irlès‐Depé, M., Grottes, H. M. D., Chermak, F., Foucher, J., Delamarre, A., & de Lédinghen, V. (2021) · Liver International · doi:10.1111/liv.15081 · Cited by 41
Public Health Measures and Prevention of Alcohol-Associated Liver Disease
Ayares, G., Idalsoaga, F. J., Arnold, J., Fuentes–López, E., Arab, J. P., & Díaz, L. A. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.05.005 · Cited by 41
Self-citationEffects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease
Kawamura, Y., Arase, Y., Ikeda, K., Akuta, N., Kobayashi, M., Saitoh, S., Suzuki, F., Suzuki, Y., Inao, M., Mochida, S., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.11.019 · Cited by 40
Neufeld, M., Rovira, P., Ferreira‐Borges, C., Kilian, C., Sassi, F., Veryga, A., & Rehm, J. T. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100325 · Cited by 40
The Changing Epidemiology of Alcohol-Associated Liver Disease: Gender, Race, and Risk Factors
Anouti, A., & Mellinger, J. L. (2022) · Seminars in Liver Disease · doi:10.1055/a-2000-6680 · Cited by 40
Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD
Blomdahl, J., Nasr, P., Ekstedt, M., & Kechagias, S. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000003 · Cited by 40
Barbier‐Torres, L., Murray, B., Yang, J. W., Wang, J., Matsuda, M., Robinson, A., Binek, A., Fan, W., Fernández‐Ramos, D., Lopitz‐Otsoa, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28201-2 · Cited by 40
FXR and NASH: an avenue for tissue-specific regulation
Henry, Z. R., Meadows, V., & Guo, G. L. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000127 · Cited by 38
Key Signaling in Alcohol-Associated Liver Disease: The Role of Bile Acids
Way, G. W., Jackson, K. G., Muscu, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11081374 · Cited by 36
Mathur, M., Yeh, Y.-T., Arya, R. K., Jiang, L., Pornour, M., Chen, W.-P., Ma, Y.-Y., Gao, B., He, L., Ying, Z., et al. (2022) · Hepatology · doi:10.1002/hep.32675 · Cited by 36
Advances in the genetics of nonalcoholic fatty liver disease
Ajmera, V. H., & Loomba, R. S. (2023) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000927 · Cited by 36
Krag, A. A., Buti, M., Lazarus, J. V., Allen, A. M., Bowman, J., Burra, P., Donnini, G., Duseja, A. K., El-Sayed, M. H., Gastaldelli, A., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.029 · Cited by 36
Yamada, T., Fukatsu, M., Suzuki, S., Yoshida, T., Tokudome, S., & Joh, T. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0693-0 · Cited by 34
A novel role for ceramide synthase 6 in mouse and human alcoholic steatosis
Williams, B., Correnti, J. M., Oranu, A. C., Lin, A., Scott, V. M., Annoh, M., Beck, J., Furth, E. E., Mitchell, V., Senkal, C. E., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201601142r · Cited by 34
An Experimental DUAL Model of Advanced Liver Damage
Benedé‐Ubieto, R., Estévez‐Vázquez, O., Guo, F., Chen, C., Singh, Y., Nakaya, H. I., del Moral, M. G., Lamas‐Paz, A., Morán, L., López‐Alcántara, N., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1698 · Cited by 34
Self-citationPathogenesis of Alcohol-Associated Fatty Liver: Lessons From Transgenic Mice
Ferdouse, A., & Clugston, R. D. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.940974 · Cited by 33
Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity
Innes, H. A., Crooks, C. J., Aspinall, E., Card, T. R., Hamill, V., Dillon, J. F., Guha, I. N., Hayes, P. C., Hutchinson, S. J., West, J., et al. (2021) · Hepatology · doi:10.1002/hep.32123 · Cited by 31
NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population
Thomas, C. E., Diergaarde, B. B., Kuipers, A. L., Adibi, J. J., Luu, H. N., Chang, X., Dorajoo, R., Heng, C., Khor, C. C., Wang, R., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1976 · Cited by 31
Old and New Biomarkers of Alcohol Abuse: Narrative Review
Fakhari, S., & Waszkiewicz, N. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062124 · Cited by 30
Nuclear receptors and non-alcoholic fatty liver disease: An update
Xiao, Y., Gonzalez, F. J., Huang, M., & Bi, H. (2020) · Liver Research · doi:10.1016/j.livres.2020.03.001 · Cited by 29
Eroglu, E. I., Huang, B., Ahmadi, M. N., Johnson, N. A., El-Omar, E. M., & Stamatakis, E. A. (2021) · European Journal of Clinical Nutrition · doi:10.1038/s41430-021-00923-4 · Cited by 28
Magherman, L., Parys, R. V., Pauwels, N., Verhelst, X., Devisscher, L., Vlierberghe, H. V., Geerts, A. M., & Lefere, S. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17388 · Cited by 28
Chen, H., Zhang, Y., Guo, T., Yang, F., Mao, Y., Li, L., Liu, C., Gao, H., Jin, Y., Che, Y., et al. (2020) · Liver International · doi:10.1111/liv.14616 · Cited by 27
Emerging targets for therapy in ALD: Lessons from NASH
Singal, A. K., Shah, V. H., & Malhi, H. (2023) · Hepatology · doi:10.1097/hep.0000000000000381 · Cited by 26
Eguchi, A., Iwasa, M., & Nakagawa, H. (2022) · Liver International · doi:10.1111/liv.15490 · Cited by 24
Molecular mechanisms of autophagy and implications in liver diseases
Wu, Y., Tan, H. W. S., Lin, J.-Y., Shen, H., Wang, H., & Lu, G. X. (2023) · Liver Research · doi:10.1016/j.livres.2023.02.002 · Cited by 24
Maccioni, L., Loriot, A., Dewulf, J., Bommer, G., Horsmans, Y., Lanthier, N., Leclercq, I., Schnabl, B., & Stärkel, P. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17177 · Cited by 23
A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression
Delacôte, C., Bauvin, P., Louvet, A., Dautrecque, F., Wandji, L. C. N., Lassailly, G., Voican, C. S., Perlemuter, G., Naveau, S., Mathurin, P., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.12.041 · Cited by 22
Self-citationEffects of Moderate Alcohol Consumption in Non-Alcoholic Fatty Liver Disease
Lemmer, P., Manka, P. P., Best, J., Kahraman, A., Kälsch, J., Vilchez‐Vargas, R., Link, A., Chiang, H., Gerken, G., Canbay, A. E., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030890 · Cited by 22
Bajaj, J. S., & Nagy, L. E. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.05.031 · Cited by 21
Marrero, I., Maricic, I., Morgan, T. R. M., Stolz, A., Schnabl, B., Liu, Z., Tsukamoto, H., & Kumar, V. (2020) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14323 · Cited by 19
Janjua, M., Knuiman, M. W., Divitini, M., McQuillan, B., Olynyk, J. K., Jeffrey, G. P., & Adams, L. A. (2021) · Hepatology Communications · doi:10.1002/hep4.1828 · Cited by 12
Pirola, C. J., & Sookoian, S. C. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2191190 · Cited by 12
Modest Alcohol Consumption has an Inverse Association with Liver Fat Content
Gunji, T., Satō, H., Iijima, K., Fujibayashi, K., Okumura, M., Sasabe, N., & Matsuhashi, N. (2012) · Hepatogastroenterology · doi:10.5754/hge12175 · Cited by 11
Superoxide Dismutase 2 Genetic Variation as a Susceptibility Risk Factor for Alcoholic Cirrhosis
Huang, Y., Wang, L. Y., Chang, C., Perng, C., & Lin, H. (2016) · Alcohol and Alcoholism · doi:10.1093/alcalc/agw004 · Cited by 10
The natural history of alcohol-related liver disease
Parker, R. (2020) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000627 · Cited by 8
Tan, E. Z., Lai, L. L., Vethakkan, S. R., Mustapha, N. R. N., Mahadeva, S., & Chan, W. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15160 · Cited by 8
Intrahepatic triglyceride content: influence of metabolic and genetics drivers
Dearlove, D., & Hodson, L. (2022) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000838 · Cited by 8
Neufeld, M., Rovira, P., Ferreira‐Borges, C., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4006130 · Cited by 2
Research works printed but not linked: 2
- Hajduch, E., Lachkar, F., Ferré, P. & Foufelle, F. Roles of ceramides in non-alcoholic fatty liver disease. J. Clin. Med. Res. 10, 792 (2021).
- European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016).
Cited by
Sorted by citations
Alcohol-associated liver disease
Mackowiak, B., Fu, Y., Maccioni, L., & Gao, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176345 · Cited by 359
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Hwang, S. Y., Danpanichkul, P., Agopian, V. G., Mehta, N., Parikh, N. D., Abou‐Alfa, G. K., Singal, A. G., & Yang, J. D. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0824 · Cited by 359
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki‐Järvinen, H., & Loomba, R. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 365
Arab, J. P., Díaz, L. A., Rehm, J. T., Im, G. Y., Arrese, M. A., Kamath, P. S., Lucey, M. R., Mellinger, J. L., Thiele, M. S., Thursz, M. R., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.11.028 · Cited by 193
Self-citationIsraelsen, M., Torp, N., Johansen, S., Hansen, C. D., Hansen, E. D., Thorhauge, K., Hansen, J. K., Villesen, I., Bech, K., Wernberg, C., et al. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00443-0 · Cited by 174
Metadata
- Authors
- Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M.
- Affiliations
- Pontificia Universidad Católica de Chile (CL)
- Western University (CA)
- Inserm (FR)
- Corresponding author
- Arrese, Marco
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2023-08-15
- Volume
- 20
- Issue
- 12
- Pages
- 764-783
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W4385851156
- Semantic Scholar
- f457122280dbd0b72d6e068cbffa2b2fe281bb04
- Cited by
- 207
- References
- 252
- Citations by year
- 2026: 58 · 2025: 75 · 2024: 63 · 2023: 11
- FWCI
- 8.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (U01AA021908, U01AA020821)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, alcoholic liver disease, metabolic syndrome, hepatic steatosis, alcohol consumption, alcohol biomarkers, disease classification, pathogenesis, chronic liver disease
- MeSH terms
- Alcohol Drinking, Ethanol, Humans, Biomarkers, Metabolic Syndrome, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
